Future Science Group today announced the relaunch of Oncology Central, the information hub designed exclusively for medical professionals in the field of oncology. Oncology is a fast-moving, multidisciplinary field at the forefront of medical research and Oncology Central unites all aspects to support multilateral progression in the field.
'We are delighted to bring you the new Oncology Central, redesigned to make it even easier for you to stay up-to-date in this fast-moving field,' said Emily Brown, editor of Oncology Central. 'With its intuitive new design, all our excellent content across all therapeutic areas is at your fingertips.'
Oncology Central is a free-of-charge platform where peer-reviewed journal articles from highly valued journals, regular cancer news updates, exciting multimedia content, and exclusive features can all be digested quickly and easily. With even more content, the fully redesigned Oncology Central is even easier to navigate, saving you time when you need to search by a specific disease area or topic.
The relaunch sees the addition of new site features including a dedicated Pipelines and Trials section, which allows easy access to all phase trials and pipelines by discipline breakdown so you can keep an eye on future therapeutic prospects. Webinars have also been introduced to keep you up to speed on vital areas and allow opportunity to pose questions to fellow experts -- see Oncology Central's pioneering webinar on stereotactic radiosurgery for brain metastases.
In celebration of the relaunch of Oncology Central, we are featuring a special collection of recent peer-reviewed articles discussing cancer immunotherapy strategies. These include an excellent review of anti-PD1 and anti-PD-L1 therapies in the treatment of metastatic melanoma -- a key topic highlighted in the Plenary Session of the recent ASCO meeting.
Register for access here - http://www.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.